The latest analyst coverage could presage a bad day for BridgeBio Pharma, Inc. ( NASDAQ:BBIO ), with the analysts...
BridgeBio Pharma ( NASDAQ:BBIO ) First Quarter 2024 Results Key Financial Results Revenue: US$211.1m (up by US$209.3m...
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abst